Progress report on new antiepileptic drugs: A summary of The Fourth Eilat Conference (EILAT IV)

M. Bialer, S. I. Johannessen, H. J. Kupferberg, R. H. Levy, P. Loiseau, E. Perucca

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

The Fourth Eilat Conference on New Antiepileptic Drugs (AEDs) was held at the Royal Beach Hotel, Eilat, Israel, from 6th to 10th September 1998. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss a number of issues in drug development, including outcome assessment in epilepsy (long-term efficacy, quality of life, safety), cost-effectiveness, an update on drugs in development, a progress report on recently marketed AEDs, and controversies in strategies for drug development. This review focuses on drugs in development and recently marketed AEDs. Drugs in development include ADCI; AWD 131-138, DP16, ganaxolone (CCD 1042), levetiracetam (ucb L059), losigamone, pregabalin (isobutyl GABA [CI-1008]), remacemide hydrochloride, retigabine (D-23129), rufinamide (CGP 33101), soretolide (D2916), TV1901, and 534U87. New information off the safety and efficacy of recently marketed drugs (felbamate, fosphenytoin, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide) and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. This paper summarizes the presentations made at the conference.

Original languageEnglish
Pages (from-to)1-41
Number of pages41
JournalEpilepsy Research
Volume34
Issue number1
DOIs
Publication statusPublished - Mar 1999

Fingerprint

Anticonvulsants
etiracetam
Pharmaceutical Preparations
zonisamide
felbamate
Vigabatrin
losigame
Safety
Israel
gamma-Aminobutyric Acid
Prostheses and Implants
Cost-Benefit Analysis
Epilepsy
Quality of Life
Outcome Assessment (Health Care)
Equipment and Supplies
ezogabine
soretolide
ganaxolone
rufinamide

Keywords

  • Antiepileptic drugs
  • Clinical trials
  • Drug development
  • Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Progress report on new antiepileptic drugs : A summary of The Fourth Eilat Conference (EILAT IV). / Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E.

In: Epilepsy Research, Vol. 34, No. 1, 03.1999, p. 1-41.

Research output: Contribution to journalArticle

Bialer, M. ; Johannessen, S. I. ; Kupferberg, H. J. ; Levy, R. H. ; Loiseau, P. ; Perucca, E. / Progress report on new antiepileptic drugs : A summary of The Fourth Eilat Conference (EILAT IV). In: Epilepsy Research. 1999 ; Vol. 34, No. 1. pp. 1-41.
@article{ccff72a63b3249cb90eccfaf21d5c919,
title = "Progress report on new antiepileptic drugs: A summary of The Fourth Eilat Conference (EILAT IV)",
abstract = "The Fourth Eilat Conference on New Antiepileptic Drugs (AEDs) was held at the Royal Beach Hotel, Eilat, Israel, from 6th to 10th September 1998. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss a number of issues in drug development, including outcome assessment in epilepsy (long-term efficacy, quality of life, safety), cost-effectiveness, an update on drugs in development, a progress report on recently marketed AEDs, and controversies in strategies for drug development. This review focuses on drugs in development and recently marketed AEDs. Drugs in development include ADCI; AWD 131-138, DP16, ganaxolone (CCD 1042), levetiracetam (ucb L059), losigamone, pregabalin (isobutyl GABA [CI-1008]), remacemide hydrochloride, retigabine (D-23129), rufinamide (CGP 33101), soretolide (D2916), TV1901, and 534U87. New information off the safety and efficacy of recently marketed drugs (felbamate, fosphenytoin, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide) and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. This paper summarizes the presentations made at the conference.",
keywords = "Antiepileptic drugs, Clinical trials, Drug development, Epilepsy",
author = "M. Bialer and Johannessen, {S. I.} and Kupferberg, {H. J.} and Levy, {R. H.} and P. Loiseau and E. Perucca",
year = "1999",
month = "3",
doi = "10.1016/S0920-1211(98)00108-9",
language = "English",
volume = "34",
pages = "1--41",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Progress report on new antiepileptic drugs

T2 - A summary of The Fourth Eilat Conference (EILAT IV)

AU - Bialer, M.

AU - Johannessen, S. I.

AU - Kupferberg, H. J.

AU - Levy, R. H.

AU - Loiseau, P.

AU - Perucca, E.

PY - 1999/3

Y1 - 1999/3

N2 - The Fourth Eilat Conference on New Antiepileptic Drugs (AEDs) was held at the Royal Beach Hotel, Eilat, Israel, from 6th to 10th September 1998. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss a number of issues in drug development, including outcome assessment in epilepsy (long-term efficacy, quality of life, safety), cost-effectiveness, an update on drugs in development, a progress report on recently marketed AEDs, and controversies in strategies for drug development. This review focuses on drugs in development and recently marketed AEDs. Drugs in development include ADCI; AWD 131-138, DP16, ganaxolone (CCD 1042), levetiracetam (ucb L059), losigamone, pregabalin (isobutyl GABA [CI-1008]), remacemide hydrochloride, retigabine (D-23129), rufinamide (CGP 33101), soretolide (D2916), TV1901, and 534U87. New information off the safety and efficacy of recently marketed drugs (felbamate, fosphenytoin, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide) and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. This paper summarizes the presentations made at the conference.

AB - The Fourth Eilat Conference on New Antiepileptic Drugs (AEDs) was held at the Royal Beach Hotel, Eilat, Israel, from 6th to 10th September 1998. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss a number of issues in drug development, including outcome assessment in epilepsy (long-term efficacy, quality of life, safety), cost-effectiveness, an update on drugs in development, a progress report on recently marketed AEDs, and controversies in strategies for drug development. This review focuses on drugs in development and recently marketed AEDs. Drugs in development include ADCI; AWD 131-138, DP16, ganaxolone (CCD 1042), levetiracetam (ucb L059), losigamone, pregabalin (isobutyl GABA [CI-1008]), remacemide hydrochloride, retigabine (D-23129), rufinamide (CGP 33101), soretolide (D2916), TV1901, and 534U87. New information off the safety and efficacy of recently marketed drugs (felbamate, fosphenytoin, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide) and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. This paper summarizes the presentations made at the conference.

KW - Antiepileptic drugs

KW - Clinical trials

KW - Drug development

KW - Epilepsy

UR - http://www.scopus.com/inward/record.url?scp=0033061573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033061573&partnerID=8YFLogxK

U2 - 10.1016/S0920-1211(98)00108-9

DO - 10.1016/S0920-1211(98)00108-9

M3 - Article

C2 - 10194110

AN - SCOPUS:0033061573

VL - 34

SP - 1

EP - 41

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -